论文部分内容阅读
目的了解英夫利西单抗及来氟米特联合应用对早期严重类风湿性关节炎的临床疗效。方法 87例早期严重类风湿性关节炎患者随机分为英夫利西单抗组、英夫利西单抗联合来氟米特组及来氟米特组,治疗前作相应的临床、实验室检查后,英夫利西单抗以每次剂量3mg/kg静滴,0,2,6周以后每隔8周用药1次;来氟米特20mg/d,治疗后对患者临床观察指标进行比较,并进行疗效评价。结果英夫利西单抗联合来氟米特组治疗24周后,关节炎症状明显得以控制,达到美国风湿学会症状体征20%改善(ACR20)、美国风湿学会症状体征50%改善(ACR50)、美国风湿学会症状体征70%改善(ACR70)的分别为90%、66%及34%,与另外二组比较差异有统计学意义(P<0.01)。结论英夫利西单抗与来氟米特联合应用对早期严重类风湿性关节炎有显著疗效。
Objective To investigate the clinical effect of combination therapy of infliximab and leflunomide on early severe rheumatoid arthritis. Methods 87 cases of early severe rheumatoid arthritis were randomly divided into infliximab group, infliximab combined with leflunomide group and leflunomide group, before treatment for the corresponding clinical and laboratory tests, Xidan at each dose of 3mg / kg intravenous infusion, 0,2,6 weeks after the medication once every 8 weeks; leflunomide 20mg / d, the clinical observation of patients after treatment indicators were compared and the efficacy evaluation. Results After 24 weeks of treatment with infliximab and leflunomide, the symptoms of arthritis were significantly controlled, reaching 20% improvement in symptom and signs of Rheumatoid Arthritis (ACR20), 50% improvement in symptoms and signs of rheumatoid arthritis (ACR50), rheumatism The 70% improvement in symptom and signs (ACR70) was 90%, 66% and 34%, respectively, which was significantly different from the other two groups (P <0.01). Conclusion The combination of infliximab and leflunomide has a significant effect on early severe rheumatoid arthritis.